4.6 Review

Non-invasive molecular imaging of kidney diseases

Journal

NATURE REVIEWS NEPHROLOGY
Volume 17, Issue 10, Pages 688-703

Publisher

NATURE PORTFOLIO
DOI: 10.1038/s41581-021-00440-4

Keywords

-

Funding

  1. German Research Foundation (DFG) [SFB/TRR57 P25P33, SFB/TRR219, 322900939, BO3755/13-1, 454024652, 331065168]
  2. German Federal Ministry of Education and Research [BMBF: STOP-FSGS-01GM1901A]
  3. German Federal Ministry of Economic Affairs and Energy (BMWi: EMPAIA project)
  4. Medical Faculty of the RWTH Aachen [START 109/20]
  5. European Research Council [ERC: CoG-864121, 101001791]
  6. ITN INTRICARE of European Union's Horizon 2020 research and innovation programme [722609]
  7. Marie Curie Actions (MSCA) [722609] Funding Source: Marie Curie Actions (MSCA)
  8. European Research Council (ERC) [101001791] Funding Source: European Research Council (ERC)

Ask authors/readers for more resources

Non-invasive molecular imaging techniques in nephrology have the potential to improve clinical research and practices, but current diagnostic and treatment methods are limited. Molecular imaging can help to non-invasively and quantitatively assess renal disease processes, providing effective guidance for clinical research and treatment.
In vivo non-invasive molecular imaging techniques have potential to improve clinical research and practices in nephrology. Here, the authors discuss the benefits and challenges of preclinical and clinical applications of molecular imaging to acute kidney injury and chronic kidney disease, transplantation and kidney cancer. In nephrology, differential diagnosis or assessment of disease activity largely relies on the analysis of glomerular filtration rate, urinary sediment, proteinuria and tissue obtained through invasive kidney biopsies. However, currently available non-invasive functional parameters, and most serum and urine biomarkers, cannot capture intrarenal molecular disease processes specifically. Moreover, although histopathological analyses of kidney biopsy samples enable the visualization of pathological morphological and molecular alterations, they only provide information about a small part of the kidney and do not allow longitudinal monitoring. These limitations not only hinder understanding of the dynamics of specific disease processes in the kidney, but also limit the targeting of treatments to active phases of disease and the development of novel targeted therapies. Molecular imaging enables non-invasive and quantitative assessment of physiological or pathological processes by combining imaging technologies with specific molecular probes. Here, we discuss current preclinical and clinical molecular imaging approaches in nephrology. Non-invasive visualization of the kidneys through molecular imaging can be used to detect and longitudinally monitor disease activity and can therefore provide companion diagnostics to guide clinical trials, as well as the safe and effective use of drugs.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available